tradmap

CRBU Caribou Biosciences, Inc.

$1.64 +0.00%

Healthcare · Biological Products, (No Diagnostic Substances)

Caribou Biosciences, Inc. (CRBU) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $163 million. Shares last traded at $1.64, 79.3% below their 52-week high. Over the past year the stock is up 42.6%. Net profit margin is -1327.4%, below the peer median of 6.3%. Revenue grew 11.7% year over year.

Market Cap
$163M
Shares Out
99.2M
EPS (TTM)
$-3.01
P/E Ratio
P/S Ratio
14.58
P/B Ratio
1.59
Dividend / Share
Dividend Yield
52-Week High
$7.93
52-Week Low
$1.13
Volume
204,907
Avg Vol (3m)
87,271.698

Performance

1W
-1.20%
1M
-16.75%
3M
-16.54%
6M
-2.67%
YTD
+3.14%
1Y
+42.61%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
34.75
SMA (50)
$2.02
SMA (200)
$1.94
Price vs SMA50
-18.87%
Price vs SMA200
-15.41%
ATR (14)
$0.14

Financials

Revenue
$11M
Net Income
$-148M
Gross Margin
Operating Margin
-1329.4%
Net Margin
-1327.4%
Return on Equity
-145.2%
Return on Assets
-99.4%
Current Ratio
6.22
Debt / Equity
0.46
Revenue Growth (YoY)
+11.7%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.26 2026-05-07
FY 2025 $-1.59 2026-03-05
Q3 2025 $-1.31 2025-11-12
Q2 2025 $-1.01 2025-08-12
Q1 2026 $-0.43 2026-05-07
FY 2025 $-1.65 2026-03-05

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

CRBU vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
14.58 / 5.21 med
+180% premium
Net margin vs peers
-1327.4% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.